Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614167 | 0.85 | BCHE (0.63) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL10729336 | 0.84 | BCHE (0.67) | BCHEKDM4EHPGDHTTALDH1A1 | |
| Bromide SCHEMBL10779800 | 0.83 | BCHE (0.76) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL19160266 | 0.82 | BCHE (0.79) | BCHEKDM4EHTTALDH1A1MAPT | |
| SCHEMBL14376841 | 0.81 | BCHE (0.69) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL1375397 | 0.81 | BCHE (0.57) | BCHEKDM4EHPGDHTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL10777379 | 0.81 | BCHE (0.82) | BCHEKDM4EHTTALDH1A1MAPT | |
| SCHEMBL13934506 | 0.81 | BCHE (0.72) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL15342480 | 0.81 | BCHE (0.44) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL10202194 | 0.80 | BCHE (0.56) | BCHEKDM4EHTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-30 | — | — | US | disclosed |
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3490983-B1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020023355-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2018026620-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-08 | — | — | WO | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | COLEY PHARMACEUTICAL GROUP, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | COLEY PHARMACEUTICAL GROUP, INC. | 2007-11-08 | — | — | US | disclosed |
| US-7247756-B2 | 1,4-disubstituted benzenes as insecticides | BAYER CROPSCIENCE AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-7247756-B2 | 1,4-disubstituted benzenes as insecticides | BAYER CROPSCIENCE AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259881-A1 | Substituted Imidazo Ring Systems and Methods | IL2, IL4, IRF3 | BCHE 3237/4885KDM4E 3339/4885HPGD 530/4885 |
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | TLR9, TLR7, TLR8 | BCHE 4791/4885KDM4E 730/4885HPGD 4352/4885 |
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | BCHE 1485/4885KDM4E 3996/4885HPGD 3618/4885 |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | BCHE 794/4885KDM4E 437/4885HPGD 103/4885 |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | BCHE 4718/4885KDM4E 1915/4885HPGD 3718/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | BCHE 2461/4885KDM4E 1488/4885HPGD 1358/4885 |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | TLR9, TLR7, TLR8 | BCHE 4783/4885KDM4E 717/4885HPGD 4348/4885 |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | BCHE 4178/4885KDM4E 3312/4885HPGD 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.